<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; NLTX</title>
	<atom:link href="http://www.stockbloghub.com/tag/nltx/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(NBIX) Focus Turns To Biotech Next Week</title>
		<link>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740</link>
		<comments>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740#comments</comments>
		<pubDate>Tue, 11 Jan 2011 23:46:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Aastrom Biosciences Inc]]></category>
		<category><![CDATA[ACAD]]></category>
		<category><![CDATA[ACADIA Pharmaceuticals Inc]]></category>
		<category><![CDATA[ASTM]]></category>
		<category><![CDATA[Cytomedix Inc]]></category>
		<category><![CDATA[Cytori Therapeutics Inc]]></category>
		<category><![CDATA[CYTX]]></category>
		<category><![CDATA[DATA]]></category>
		<category><![CDATA[DATATRAK International Inc]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[GTF]]></category>
		<category><![CDATA[NBIX]]></category>
		<category><![CDATA[Neurocrine Biosciences Inc]]></category>
		<category><![CDATA[Nile Therapeutics Inc]]></category>
		<category><![CDATA[NLTX]]></category>
		<category><![CDATA[OXBT]]></category>
		<category><![CDATA[Oxygen Biotherapeutics]]></category>
		<category><![CDATA[PBIO]]></category>
		<category><![CDATA[POZEN Inc]]></category>
		<category><![CDATA[POZN]]></category>
		<category><![CDATA[Pressure BioSciences Inc.]]></category>
		<category><![CDATA[SPEX]]></category>
		<category><![CDATA[Spherix Inc]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=64740</guid>
		<description><![CDATA[Focus Turns To Biotech Next Week The week of January 10th is perhaps one of the biggest weeks in the biotechnology  industry. Three significant healthcare conferences will take place in San Francisco, headlined by the 29th annual J.P. Morgan Healthcare Conference held at the Westin St. Francis Hotel. The event is attended by the “Who’s Who” of the healthcare industry, with currently over 350 companies registered to attend. Two smaller conferences will also take place next week concurrent with the massive J.P. Morgan conference, the 4th annual OneMed Forum 2011 held at the Sir Francis Drake Hotel and the Biotech Showcase 2011 held at the Parc 55 Wyndham Hotel feature smaller companies from the biotech and medical device industries. These conferences are an outstanding opportunity for biotech investors to meet ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/11/nbix-focus-turns-to-biotech-next-week/64740/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NLTX) Nile Therapeutics Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2010/08/20/nltx-nile-therapeutics-incorporated-bull-of-the-day/48640</link>
		<comments>http://www.stockbloghub.com/2010/08/20/nltx-nile-therapeutics-incorporated-bull-of-the-day/48640#comments</comments>
		<pubDate>Fri, 20 Aug 2010 15:45:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Nile Therapeutics Inc]]></category>
		<category><![CDATA[NLTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48640</guid>
		<description><![CDATA[Nile Therapeutics, Inc. (NLTX) is developing CD-NP, a chimeric natriuretic peptide currently in phase II clinical studies for the treatment of acute decompensated heart failure (ADHF). Prior phase I and phase II data so far has been highly encouraging. With a market capitalization of only $14 million, Nile Therapeutics shares are bafflingly under-valued. We believe with positive data from the ongoing phase II program in hand the company is worth at least $80 to 100 million. Taking the mid-range at $90 million, and then backing out the $20 million most likely required to fund the phase IIb program, we arrive at a value of $70 million for Nile Therapeutics. This equates to a price of $2.00 per share. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/20/nltx-nile-therapeutics-incorporated-bull-of-the-day/48640/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NLTX) Nile Therapeutics Pushing Forward with CD-NP</title>
		<link>http://www.stockbloghub.com/2010/03/08/nltx-nile-therapeutics-pushing-forward-with-cd-np/29938</link>
		<comments>http://www.stockbloghub.com/2010/03/08/nltx-nile-therapeutics-pushing-forward-with-cd-np/29938#comments</comments>
		<pubDate>Mon, 08 Mar 2010 15:54:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Nile Therapeutics Inc]]></category>
		<category><![CDATA[NLTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29938</guid>
		<description><![CDATA[On March 3, 2010, Nile Therapeutics (NLTX) reported financial results for the fourth quarter and full year 2009. Nile reported no revenues for the fourth quarter or full year 2009. Net loss for the fourth quarter totaled $1.6 million, or $0.06 per diluted share. For the full-year 2009, Nile reported a net loss of approximately $7.9 million, or $0.31 per diluted share. Nile exited 2009 with roughly $3.2 million in cash and investments. We believe this is sufficient cash to complete the ongoing phase II program and fund operations into the second half of the year. Update on CD-NP In June 2009, Nile initiated a phase II open-label, single-blind, placebo-control program designed to determine a safe and tolerable dose range of CD-NP that can be used in ADHF (acute decompensated ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/08/nltx-nile-therapeutics-pushing-forward-with-cd-np/29938/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NLTX) Nile Therapeutics Coverage Initiated at Outperform</title>
		<link>http://www.stockbloghub.com/2010/01/27/nltx-nile-therapeutics-coverage-initiated-at-outperform/26221</link>
		<comments>http://www.stockbloghub.com/2010/01/27/nltx-nile-therapeutics-coverage-initiated-at-outperform/26221#comments</comments>
		<pubDate>Thu, 28 Jan 2010 01:43:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Nile Therapeutics Inc]]></category>
		<category><![CDATA[NLTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26221</guid>
		<description><![CDATA[We are initiating coverage of Nile Therapeutics (NLTX) with an Outperform rating and a near-term price target of $2.50 per share. Nile is developing CD-NP, a chimeric natriuretic peptide currently in phase II clinical studies for the treatment of acute decompensated heart failure (ADHF). This is a highly coveted area by large-cap pharmaceutical companies. The opportunity is wide-open, and a significant breakthrough product could capture blockbuster sales a few years after launch. For example, Johnson &#38; Johnson’s Natrecor (nesiritide) was annualizing at $400 million in sales &#8212; and on its way toward a billion &#8212; in 2004 prior to the safety issues that still today dramatically limit the product&#8217;s uptake. Heart Failure Treatment at Present Standard of care is a mixture of vasodilators, diuretics and inotropic agents, almost all available ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/27/nltx-nile-therapeutics-coverage-initiated-at-outperform/26221/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NLTX) Nile Therapeutics Initiated at Outperform by Analysts</title>
		<link>http://www.stockbloghub.com/2010/01/27/nltx-nile-therapeutics-initiated-at-outperform-by-analysts/26160</link>
		<comments>http://www.stockbloghub.com/2010/01/27/nltx-nile-therapeutics-initiated-at-outperform-by-analysts/26160#comments</comments>
		<pubDate>Wed, 27 Jan 2010 18:46:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Nile Therapeutics Inc]]></category>
		<category><![CDATA[NLTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=26160</guid>
		<description><![CDATA[We are initiating coverage of Nile Therapeutics (NLTX) with an Outperform rating and a near-term price target of $2.50 per share. Nile is developing CD-NP, a chimeric natriuretic peptide currently in phase II clinical studies for the treatment of acute decompensated heart failure (ADHF). This is a highly coveted area by large-cap pharmaceutical companies. The opportunity is wide-open, and a significant breakthrough product could capture blockbuster sales a few years after launch. For example, Johnson &#38; Johnson’s (JNJ) Natrecor (nesiritide) was annualizing at $400 million in sales &#8212; and on its way toward a billion &#8212; in 2004 prior to the safety issues that still today dramatically limit the product&#8217;s uptake. Heart Failure Treatment at Present Standard of care is a mixture of vasodilators, diuretics and inotropic agents, almost all ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/27/nltx-nile-therapeutics-initiated-at-outperform-by-analysts/26160/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

